Product image of Lackepila (Lacosamide) supplied by GNH India

Lackepila

Active Ingredient:
Lacosamide
Origin:
EU

Lackepila (Lacosamide)

Lacosamide, the active ingredient in Lackepila, is a sodium channel blocker presented as an oral tablet for oral use. It is employed to treat partial‑onset (focal) seizures in patients with epilepsy. The medication is indicated as adjunctive therapy to improve seizure control in adults and children.

GNH India supplies Lackepila as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution across multiple regulatory jurisdictions to ensure consistent product availability.

Manufacturer / TM Owner

Axunio Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Lacosamide is an anticonvulsant that acts on neuronal sodium channels to control focal epilepsy.
  • Partial‑onset seizures: reduces seizure frequency when used as adjunctive therapy in epilepsy patients.
  • Focal epilepsy: improves overall seizure control as part of a comprehensive treatment plan.
  • Adjunctive therapy for refractory focal seizures: provides additional seizure reduction when combined with other antiepileptics.

How It Works

  • Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilizing the inactive state of these channels, it reduces the ability of hyperexcitable neurons to fire repetitive action potentials, thereby diminishing the propagation of epileptic discharges. This selective modulation of sodium channel kinetics contributes to seizure control without markedly affecting normal neuronal activity in the central nervous system.

Side Effects

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Dizziness: sensation of light‑headedness or unsteadiness.
  • Nausea: mild to moderate stomach upset.
  • Headache: transient cranial pain.
  • Fatigue: feeling of tiredness or reduced energy.
  • Blurred vision: temporary visual disturbances.
  • Tremor: involuntary shaking of limbs.

Serious or Rare Side Effects

  • Cardiac arrhythmia: irregular heart rhythm, including PR‑interval prolongation.
  • Suicidal ideation: emergence of thoughts of self‑harm.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Liver enzyme elevation: increase in hepatic transaminases.
  • Life‑threatening hypersensitivity reactions: anaphylaxis or angioedema.

Precautions & Warnings

  • When prescribing Lacosamide, clinicians should consider several safety measures to minimize risk.
  • Renal impairment: adjust dose in patients with reduced kidney function.
  • Cardiac monitoring: observe ECG for PR‑interval changes in patients with heart disease.
  • Concomitant CNS depressants: use caution as additive sedation may occur.
  • Pregnancy: evaluate risk‑benefit as safety data are limited.
  • Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Avoid Interactions

Lacosamide can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

  • Class I antiarrhythmics (e.g., quinidine): may increase risk of cardiac conduction abnormalities.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise lacosamide plasma concentrations.

Moderate Interactions (Monitor Closely)

  • Carbamazepine: enzyme inducer that may reduce lacosamide levels.
  • Alcohol: additive CNS depression.
  • Other antiepileptics (e.g., phenytoin): may require dose adjustments.

Frequently Asked Questions

Lackepila contains the active ingredient lacosamide and is used as an adjunctive therapy to treat partial‑onset (focal) seizures in patients with epilepsy. It helps reduce seizure frequency when added to a stable antiepileptic regimen.

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This stabilises hyperexcitable neurons, limiting repetitive firing and thereby decreasing the spread of epileptic activity in the brain.

The dose of Lackepila is individualized by the prescribing clinician based on the patient’s age, weight, renal function and response to therapy. The prescriber determines the starting dose and any subsequent titration.

Safety data for lacosamide in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and discuss options with the patient. Breastfeeding decisions should also consider the drug’s presence in milk.

To order Lackepila, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lackepila (lacosamide) differs from many traditional sodium‑channel blockers such as carbamazepine by selectively enhancing slow inactivation rather than blocking fast inactivation. This can result in a distinct side‑effect profile and may be preferred in patients who experience intolerable adverse effects with other agents.

Lackepila tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Lackepila is taken orally, usually as a whole tablet swallowed with water. It is typically administered once or twice daily, as directed by the prescriber, and should be taken with or without food according to individual tolerance.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, emergence of suicidal thoughts or behavior, and severe skin reactions like Stevens‑Johnson syndrome. Patients should be monitored for these events, and any concerning symptoms should prompt immediate medical evaluation.

Lackepila should be avoided in individuals with known hypersensitivity to lacosamide or any tablet excipients, and in patients with significant cardiac conduction disorders (e.g., second‑ or third‑degree AV block) unless closely monitored. Caution is also advised for those with severe renal impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.